A slow-down in EU medical device audits due to the long-delayed transition to the EU Medical Device Regulation is leading to ...

With more than three weeks left in the first quarter, the value of med-tech IPOs for 2025 already exceeds the funds raised ...

Lysine demethylase 6A (KDM6A) is a demethylase that plays a key role at regulating developmental gene expression signatures ...

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a high mortality rate and characterized by ...

Biopharma companies raised $2.98 billion through 59 transactions in February 2025, down from $5.91 billion across 93 deals in January. The year is off to a slower start compared to 2023, with the ...

There have been plenty of multi-billion-dollar mega mergers in the past few years but most have fallen short of their goals. In the latest edition of the BioWorld Insider podcast, Karen Carey, ...

The disclosure of a new candidate by Dewpoint Therapeutics Inc. was the latest in the percolating beta-catenin/Wnt space, where a handful of firms have been making progress.

Investigators at Pennsylvania State University have described a novel approach to combat Clostridioides difficile infection using a synthetic microbiome therapy, which offers an alternative to ...

The BioWorld Neurological Diseases Index closed 2024 down 20.27%, extending its decline from -13.4% at the end of November. After falling to -12.2% in April, the index briefly rebounded, narrowing ...

Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his resignation as director. Collins gave no ...

A new multi-omics approach to unpicking how noncoding gene variants influence the development of common chronic diseases has ...